AUGMENTIN. Proceedings of the European Symposium Scheveningen, The Netherlands June, Excerpta Medica

Similar documents
Pharmacokinetics of amoxycillin and clavulanic acid in

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

Other Beta - lactam Antibiotics

Active Constituent: Each tablet contains 500 mg cephalexin (as monohydrate) Contents: 12 [100, 300] Tablets

Active Constituent: Each tablet contains 1000 mg cephalexin (as monohydrate) Contents: 8 [100, 300] Tablets

Author - Dr. Josie Traub-Dargatz

Amoxicillin clavulanic acid spectrum

THE QUINOLONES. Third Edition. Edited by VINCENT T. ANDRIOLE. Yale University School of Medicine ACADEMIC PRESS

Cell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents

Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

Keywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing

B. PACKAGE LEAFLET 1

ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin

Cipro for gram positive cocci in urine

Cell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?

Therios 300 mg and 750 mg Palatable Tablets for Dogs

Microbiology ( Bacteriology) sheet # 7

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe

SUMMARY OF PRODUCT CHARACTERISTICS

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Principles of Antimicrobial therapy

Approved by the Food Safety Commission on September 30, 2004

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.

Objectives. Basic Microbiology. Patient related. Environment related. Organism related 10/12/2017

Pharmacology Week 6 ANTIMICROBIAL AGENTS

JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Chapter 51. Clinical Use of Antimicrobial Agents

Barriers to Intravenous Penicillin Use for Treatment of Nonmeningitis

SUMMARY OF PRODUCT CHARACTERISTICS

Recommended for Implementation at Step 7 of the VICH Process on 15 December 2004 by the VICH Steering Committee

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

Copy in the header and footer will not appear on the final printed label LAB0042 Prepared: 28/02/01 SYRINGE LABEL

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1

Clindamycin coverage streptococcus

Is erythromycin bactericidal

Role of the nurse in diagnosing infection: The right sample, every time

American Association of Feline Practitioners American Animal Hospital Association

GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS

Unique, fast-acting, and long-lasting injectables for livestock health & nutrition

running head: SUPERBUGS Humphreys 1

Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

SUMMARY OF PRODUCT CHARACTERISTICS

Int.J.Curr.Microbiol.App.Sci (2017) 6(3):

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

choice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*

SUMMARY OF PRODUCT CHARACTERISTICS

Pharmacological Evaluation of Amikacin in Neonates

SUMMARY OF PRODUCT CHARACTERISTICS

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

Pharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed

See Important Reminder at the end of this policy for important regulatory and legal information.

SUMMARY OF PRODUCT CHARACTERISTICS

GENERAL NOTES: 2016 site of infection type of organism location of the patient

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens

Health Products Regulatory Authority

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly

SUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

10/15/08. Activity of an Antibiotic. Affinity for target. Permeability properties (ability to get to the target)

SUMMARY OF PRODUCT CHARACTERISTICS. Excipients: Contains 4% w/w cetyl alcohol and 7% w/w propylene glycol.

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

Can levaquin treat group b strep

DOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3)

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

SUMMARY OF PRODUCT CHARACTERISTICS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

amoxycillin/clavulanate vs placebo in the prevention of infection after animal

Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance

Cipro for klebsiella uti

Tackling the need for new antibacterial drugs

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae

Title: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic

Inhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani

Cellulitis. Assoc Prof Mark Thomas. Conference for General Practice Auckland Saturday 28 July 2018

Post-operative surgical wound infection

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018

An Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings?

Summary of the latest data on antibiotic resistance in the European Union

General Approach to Infectious Diseases

INTRODUCTION TO WILDLIFE PHARMACOLOGY. Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre

Appropriate antimicrobial therapy in HAP: What does this mean?

National Antimicrobial Prescribing Survey

number Done by Corrected by Doctor Dr. Malik

ECHO: Management of URIs. Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018

Guideline on the conduct of efficacy studies for intramammary products for use in cattle

Curricular Components for Infectious Diseases EPA

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

folate-derived cofactors purines pyrimidines Sulfonamides sulfa drugs Trimethoprim infecting bacterium to perform DNA synthesis cotrimoxazole

Refusal EPAR for Naxcel

GARY WOODNUTT* AND VALERIE BERRY SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania

Drug Class Prior Authorization Criteria Intravenous Antibiotics

Transcription:

AUGMENTIN clavulanate-potentiated amoxycillin c Proceedings of the European Symposium Scheveningen, The Netherlands 28-29 June, 1982 Editors: E.A.P. Croydon and M.F. Michel UNIVERSITATS- BIBLIOTHEK 1983 Excerpta Medica

Introduction E.A.P. Croydon andm.f. Michel Welcoming address E.A.P. Croydon Session I: Microbiology The history and background of Augmentin 5 G.N. Rolinson Augmentin and (3-lactamases: inactivation of (3-lactamase by clavulanic acid 11 R. Labia andj. Peduzzi Antibacterial activity of amoxycillin/clavulanic acid (Augmentin) in vitro 21 A.R. White, RJ. Boon, P.J. Masters andr. Sutherland Antimicrobial activity of Augmentin in vitro 42 L. Verbist In-vitro antibacterial activity of clavulanic acid-potentiated amoxycillin 47 G. Peters and G. Pulverer Efficacy of amoxycillin/clavulanic acid against experimental infections 53 RJ. Boon, A.S. Beale, C. V. Pierce andr. Sutherland Microbiological testing of the action of Augmentin 63 H. W. Van Landuyt and A. Lambert Microcalorimetric and turbidimetric investigations of the actions of amoxycillin, 68 clavulanic acid and Augmentin on amoxycillin-resistant strains of Escherichia coli, Klebsiella and Staphylococcus aureus E. Semenitz and P. A. Casey General discussion 77 Session II: Clinical pharmacology Absorption, pharmacokinetic and metabolic studies with Augmentin 83 D. Jackson, D.L. Cooper, R. Horton, P.F. Langley, D.S. Staniforth andaj. Sutton Comparative pharmacokinetics of amoxycillin, clavulanic acid and their combi- 102 nation G. Hqffken, G. Witkowski, H. Lode and P. Koeppe VIII

Pharmacokinetics of the association amoxycillin and clavulanic acid in renal 109 insufficiency and during haemodialysis F. Dalet, E. Cabrera, T. Donate and G. Del Rio General discussion 121 The effect of amoxycillin and amoxycillin plus clavulanic acid on human bowel 125 flora H. W. Mittermayer A prospective study of the evolution of bacterial resistance to Augmentin 134 R. Labia, R. Beguin-Billecoq and P. Baron General discussion 143 Session III: Genito-urinary tract infections A clinical trial of Augmentin in urinary tract infections 147 P. Van Erps, P. Nowe and L.J. Denis Augmentin in the treatment of urinary tract infections due to amoxycillin- 153 resistant bacteria B. Leng Oral Augmentin in the treatment of urinary tract infections 161 G. Umbach, N. Lang andh. Werner Augmentin therapy of urinary tract infections in patients with neurogenic 169 disorders of micturition secondary to spinal injury E. Reiner The protective role of clavulanic acid in urinary tract infections 178 F.W. Goldstein, M.D. KitzisandJ.F. Acar Clinical experience with 3 dosage regimens of oral Augmentin in patients with 183 urinary tract infections /. Derluyn Clinical evaluation of Augmentin treatment of urinary tract infections, with a 192 study of Augmentin's serum bacteriostatic and bactericidal activity F. Crokaert.M.P. Van der Linden and E. Yourassowsky / General discussion 202 Augmentin in the treatment of urinary tract infection in pregnant women and 207 pelvic inflammatory disease H.O. Mayer, H. Jeschek and A. Kowatsch Augmentin in the treatment of gonorrhoea caused by penicillinase-producing 218 gonococci D. Tio, G.A.J. de Koning, M.C. Ansink-Schipper andr.a. Coutinho IX

General discussion 222 Session IV: Skin and soft-tissue infections The penetration of Augmentin into ischaemic ulcers of the leg 227 M.D. Kitzis, Y. Juillet, J.N. Feissinger, E. Housset andj.f. Acar Augmentin in the treatment of skin infections 234 J.P. Garrel,J.M. Sonneck.A. ThabautandJ.B. Leaute A trial of orally administered Augmentin in the treatment of post-traumatic bone 241 and joint infections D. Lippert Protection of amoxycillin by clavulanic acid from inactivation by staphylococcal 252 (3-lactamase in vivo, R. Sutherland General discussion 256 Session V: Respiratory tract infections The penetration of Augmentin into the pleural fluid 261 M.D. Kitzis, M.B. Kitzis, C. Yvelin, J.F. Acar andb. Andreassian Experience with Augmentin in the treatment of chronic bronchitis and broncho- 267 pneumonia K. Aigner, H. W. Mittermayer andr. Schindl The use of Augmentin in general practice 278 G. Kynast A comparative study of amoxycillin and Augmentin in the treatment of broncho- 282 pulmonary infections Y. Benard, J. Lemenager and C. Morel A therapeutic study of Augmentin in a chest clinic 291 G. Kapetanakis, F. W. Hulla andd. Keratzopoulos Therapy of bronchopulmonary infections due to (3-lactamase-positive micro- 298 organisms isolated by transtracheal puncture G. Ninane Evaluation of Augmentin in patients with lower respiratory tract infections and 303 severe underlying disease CD. Schwigon andf. W. Hulla General discussion 312 X

Session VI: Paediatric infections Pharmacokinetics of Augmentin in children 319 P. Begue, F. Quiniou, N. Nocquet, C. Gaillard and C. Safran A trial of orally administered Augmentin in the treatment of urinary tract 325 infection and lower respiratory tract infection in a children's hospital M. Fink and W. Swoboda Effectiveness of Augmentin in the treatment of urinary tract infections in children 334 C. Kattamis, V. Syriopoulou, M. Papagregoriou-Theodoridou, G. Mostrou- Antonellou and G. Tzanetou Clinical experience with oral Augmentin in the treatment of ear, nose and throat 341 infections in children R. Wielemans andj.p. Gline Experience with Augmentin in the treatment of infections in children 347 H. DebrayandA. Galland The use of Augmentin syrup for the treatment of paediatric infections in general 354 practice. An interim report A.J. Rose General discussion 360 Concluding remarks 363 E.A.P. Croydon Index of authors 366 XI